Protein Epitope (In Vitro Selection/SELEX/Combining Site) WEI XU and ANDREW D
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
"Epitope Mapping: B-Cell Epitopes". In: Encyclopedia of Life Sciences
Epitope Mapping: B-cell Advanced article Epitopes Article Contents . Introduction GE Morris, Wolfson Centre for Inherited Neuromuscular Disease RJAH Orthopaedic Hospital, . What Is a B-cell Epitope? . Epitope Mapping Methods Oswestry, UK and Keele University, Keele, Staffordshire, UK . Applications Immunoglobulin molecules are folded to present a surface structure complementary to doi: 10.1002/9780470015902.a0002624.pub2 a surface feature on the antigen – the epitope is this feature of the antigen. Epitope mapping is the process of locating the antibody-binding site on the antigen, although the term is also applied more broadly to receptor–ligand interactions unrelated to the immune system. Introduction formed of highly convoluted peptide chains, so that resi- dues that lie close together on the protein surface are often Immunoglobulin molecules are folded in a way that as- far apart in the amino acid sequence (Barlow et al., 1986). sembles sequences from the variable regions of both the Consequently, most epitopes on native, globular proteins heavy and light chains into a surface feature (comprised of are conformation-dependent and they disappear if the up to six complementarity-determining regions (CDRs)) protein is denatured or fragmented. Sometimes, by acci- that is complementary in shape to a surface structure on the dent or design, antibodies are produced against linear antigen. These two surface features, the ‘paratope’ on the (sequential) epitopes that survive denaturation, though antibody and the ‘epitope’ on the antigen, may have a cer- such antibodies usually fail to recognize the native protein. tain amount of flexibility to allow an ‘induced fit’ between The simplest way to find out whether an epitope is confor- them. -
Epstein-Barr Virus Epitope-Major Histocompatibility Complex
University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2020-03-17 Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires Anna Gil University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Hemic and Lymphatic Diseases Commons, Immune System Diseases Commons, Immunology and Infectious Disease Commons, Infectious Disease Commons, Microbiology Commons, Virus Diseases Commons, and the Viruses Commons Repository Citation Gil A, Kamga L, Chirravuri-Venkata R, Aslan N, Clark FG, Ghersi D, Luzuriaga K, Selin LK. (2020). Epstein- Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires. Open Access Articles. https://doi.org/10.1128/mBio.00250-20. Retrieved from https://escholarship.umassmed.edu/ oapubs/4191 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. RESEARCH ARTICLE Host-Microbe Biology crossm Epstein-Barr Virus Epitope–Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Downloaded from Selection of Diverse T Cell Receptor ␣ and  Repertoires Anna Gil,a Larisa Kamga,b Ramakanth Chirravuri-Venkata,c Nuray Aslan,a Fransenio Clark,a Dario Ghersi,c Katherine Luzuriaga,b Liisa K. -
Epitope Spreading: Lessons from Autoimmune Skin Diseases
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW Epitope Spreading: Lessons From Autoimmune Skin Diseases Lawrence S. Chan,*† Carol J. Vanderlugt,‡ Takashi Hashimoto,§ Takeji Nishikawa,¶ John J. Zone,** Martin M. Black,†† Fenella Wojnarowska,‡‡ Seth R. Stevens,§§ Mei Chen,† Janet A. Fairley,¶¶ David T. Woodley,*† Stephen D. Miller,‡ and Kenneth B. Gordon†‡ *Medicine Service, Section of Dermatology, Lakeside Division, VA Chicago Health Care System, Chicago, Illinois, U.S.A.; Departments of †Dermatology and ‡Microbiology and Immunology, Northwestern University Medical School, Chicago, Illinois, U.S.A.; ¶¶Department of Dermatology, Kurume University School of Medicine, Kurume, Japan; ¶Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; **Medicine Service, Section of Dermatology, Salt Lake City VA Medical Center, Salt Lake City, Utah, U.S.A.; ††Department of Dermatopathology, Guy’s and St. Thomas Medical and Dental School, London, U.K.; ‡‡Department of Dermatology, The Oxford Radcliffe Hospital, Oxford, U.K.; §§Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.; ¶¶Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Autoimmune diseases are initiated when patients develop In experimental autoimmune animal diseases, ‘‘epitope aberrant T and/or B cell responses against self proteins. spreading’’ seems to have significant physiologic impor- These responses -
A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding
Article A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Jihyun Yang 1,† , Eunjin Kim 1,2,†, Jong-Soo Lee 2 and Haryoung Poo 1,* 1 Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea; [email protected] (J.Y.); [email protected] (E.K.) 2 Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-42-860-4157 † These authors contributed equally to this study. Abstract: The ongoing COVID-19 pandemic caused by SARS-CoV-2 has posed a devastating threat worldwide. The receptor-binding domain (RBD) of the spike protein is one of the most important antigens for SARS-CoV-2 vaccines, while the analysis of CD8 cytotoxic T lymphocyte activity in preclinical studies using mouse models is critical for evaluating vaccine efficacy. Here, we immunized C57BL/6 wild-type mice and transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with the SARS-CoV-2 RBD protein to evaluate the IFN-γ-producing T cells in the splenocytes of the immunized mice using an overlapping peptide pool by an enzyme-linked immunospot assay and flow cytometry. We identified SARS-CoV-2 S395–404 as a major histocompatibility complex (MHC) class I-restricted epitope for the RBD-specific CD8 T cell responses in C57BL/6 mice. Keywords: SARS-CoV-2; cell-mediated immunity; CD8 cytotoxic T lymphocyte; epitope; vaccine Citation: Yang, J.; Kim, E.; Lee, J.-S.; Poo, H. -
Aptamer-Mediated Cancer Gene Therapy Dongxi Xiang , Sarah
Aptamer-Mediated Cancer Gene Therapy Dongxi Xiang1*, Sarah Shigdar 1*, Greg Qiao2, Shu-Feng Zhou3, Yong Li4, Ming Q Wei5, 6 1 7 8 9** Liang Qiao , Hadi Al.Shamaileh , Yimin Zhu , Conglong Zheng , Chunwen Pu and Wei Duan1** 1School of Medicine, Deakin University, Pigdons Road, Waurn Ponds, Victoria, 3217, Australia. 2 Department of Chemical and Biomolecular Engineering, Melbourne School of Engineering The University of Melbourne, Parkville, Victoria 3010, Australia 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. 4Cancer Care Centre, St George Hospital, Kogarah, NSW2217, and St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW2052, Australia 5Division of Molecular and Gene Therapies, Griffith Health Institute and School of Medical Science, Griffith University, Gold Coast, QLD 4222, Australia 6Storr Liver Unit, at the Westmead Millennium Institute, the University of Sydney at the Westmead Hospital, Westmead NSW, 2145, Australia 7Suzhou Key Laboratory of Nanobiomedicine, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, Jiangsu, China, 215123 8Department of Biology, Medical College, Dalian University, Liaoning, People’s Republic of China 9The Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Road, Dalian, Liaoning, The People's Republic of China, 116001. 1 * These authors contributed equally. ** Corresponding authors: E-mail: [email protected] (C. Pu); or [email protected] (W. Duan). 2 Abstract Cancer as a genetic disorder is one of the leading causes of death worldwide. Conventional anticancer options such as chemo- and/or radio-therapy have their own drawbacks and could not provide a cure in most cases at present. -
Lab-On-A-Chip Systems for Aptamer-Based Biosensing
micromachines Review Lab-on-a-Chip Systems for Aptamer-Based Biosensing Niazul I. Khan 1 and Edward Song 1,2,* 1 Department of Electrical and Computer Engineering, University of New Hampshire, Durham, NH 03824, USA; [email protected] 2 Materials Science Program, University of New Hampshire, Durham, NH 03824, USA * Correspondence: [email protected]; Tel.: +1-603-862-5498 Received: 6 January 2020; Accepted: 17 February 2020; Published: 20 February 2020 Abstract: Aptamers are oligonucleotides or peptides that are selected from a pool of random sequences that exhibit high affinity toward a specific biomolecular species of interest. Therefore, they are ideal for use as recognition elements and ligands for binding to the target. In recent years, aptamers have gained a great deal of attention in the field of biosensing as the next-generation target receptors that could potentially replace the functions of antibodies. Consequently, it is increasingly becoming popular to integrate aptamers into a variety of sensing platforms to enhance specificity and selectivity in analyte detection. Simultaneously, as the fields of lab-on-a-chip (LOC) technology, point-of-care (POC) diagnostics, and personal medicine become topics of great interest, integration of such aptamer-based sensors with LOC devices are showing promising results as evidenced by the recent growth of literature in this area. The focus of this review article is to highlight the recent progress in aptamer-based biosensor development with emphasis on the integration between aptamers and the various forms of LOC devices including microfluidic chips and paper-based microfluidics. As aptamers are extremely versatile in terms of their utilization in different detection principles, a broad range of techniques are covered including electrochemical, optical, colorimetric, and gravimetric sensing as well as surface acoustics waves and transistor-based detection. -
Real-Time PCR for Direct Aptamer Quantification on Functionalized
www.nature.com/scientificreports OPEN Real-time PCR for direct aptamer quantifcation on functionalized graphene surfaces Viviane C. F. dos Santos1,2*, Nathalie B. F. Almeida1,2, Thiago A. S. L. de Sousa1, Eduardo N. D. Araujo3, Antero S. R. de Andrade2 & Flávio Plentz1 In this study, we develop a real-time PCR strategy to directly detect and quantify DNA aptamers on functionalized graphene surfaces using a Staphylococcus aureus aptamer (SA20) as demonstration case. We show that real-time PCR allowed aptamer quantifcation in the range of 0.05 fg to 2.5 ng. Using this quantitative technique, it was possible to determine that graphene functionalization with amino modifed SA20 (preceded by a graphene surface modifcation with thionine) was much more efcient than the process using SA20 with a pyrene modifcation. We also demonstrated that the functionalization methods investigated were selective to graphene as compared to bare silicon dioxide surfaces. The precise quantifcation of aptamers immobilized on graphene surface was performed for the frst time by molecular biology techniques, introducing a novel methodology of wide application. DNA (deoxyribonucleic acid) aptamers are single strand oligonucleotides that presents high afnity and speci- fcity to their binders1. In comparison with traditional ligands, such as antibodies, aptamers present some advan- tages. Tey are chemically stable, cost-efective, more resistant to pH and temperature variations, and are more fexible in the design of their structures2. Due to these characteristics, they have great potential as sensing compo- nents in diagnostic and detection assays. Biosensor platforms based on DNA aptamers are more stable for storage and transport than the antibodies counterparts2. -
Heteroclitic CD8 T Cell Epitopes Enhanced Antiviral Immunity
Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes This information is current as Jonathan A. Trujillo, Stephanie Gras, Kelly-Anne Twist, of September 30, 2021. Nathan P. Croft, Rudragouda Channappanavar, Jamie Rossjohn, Anthony W. Purcell and Stanley Perlman J Immunol 2014; 192:5245-5256; Prepublished online 2 May 2014; doi: 10.4049/jimmunol.1400111 Downloaded from http://www.jimmunol.org/content/192/11/5245 References This article cites 56 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/192/11/5245.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 30, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes Jonathan A. Trujillo,*,1 Stephanie Gras,†,1 Kelly-Anne Twist,† Nathan P. -
Design Strategies for Aptamer-Based Biosensors
Sensors 2010, 10, 4541-4557; doi:10.3390/s100504541 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review Design Strategies for Aptamer-Based Biosensors Kun Han 1,2, Zhiqiang Liang 3 and Nandi Zhou 1,4,* 1 Department of Biochemistry and National Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China 2 Suzhou Institute of Biomedical Engineering Technology, Chinese Academy of Science, Suzhou 215163, China; E-Mail: [email protected] 3 Laboratory of Biosensing Technology, School of Life Sciences, Shanghai University, Shanghai 200444, China; E-Mail: [email protected] 4 School of Biotechnology and the Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +86-510-8591-8116; Fax: +86-510-8591-8116. Received: 11 February 2010; in revised form: 1 April 2010 / Accepted: 4 April 2010 / Published: 4 May 2010 Abstract: Aptamers have been widely used as recognition elements for biosensor construction, especially in the detection of proteins or small molecule targets, and regarded as promising alternatives for antibodies in bioassay areas. In this review, we present an overview of reported design strategies for the fabrication of biosensors and classify them into four basic modes: target-induced structure switching mode, sandwich or sandwich-like mode, target-induced dissociation/displacement mode and competitive replacement mode. In view of the unprecedented advantages brought about by aptamers and smart design strategies, aptamer-based biosensors are expected to be one of the most promising devices in bioassay related applications. -
Download Article (PDF)
DNA and RNA Nanotechnology 2015; 2: 42–52 Mini review Open Access Martin Panigaj*, Jakob Reiser Aptamer guided delivery of nucleic acid-based nanoparticles DOI 10.1515/rnan-2015-0005 Evolution of Ligands by Exponential enrichment) [4,5]. Received July 15, 2015; accepted October 3, 2015 Nucleic acid-based aptamers are especially well suited Abstract: Targeted delivery of bioactive compounds is a for the delivery of nucleic acid-based therapeutics. Any key part of successful therapies. In this context, nucleic nucleic acid with therapeutic potential can be linked acid and protein-based aptamers have been shown to to an aptamer sequence [6], resulting in a bivalent bind therapeutically relevant targets including receptors. molecule endowed with a targeting aptamer moiety and In the last decade, nucleic acid-based therapeutics a functional RNA/DNA moiety like a small interfering coupled to aptamers have emerged as a viable strategy for RNA (siRNA), a micro RNA (miRNA), a miRNA antagonist cell specific delivery. Additionally, recent developments (antimiR), deoxyribozymes (DNAzymes), etc. In addition in nucleic acid nanotechnology offer an abundance of to the specific binding, many aptamers upon receptor possibilities to rationally design aptamer targeted RNA recognition elicit antagonistic or agonistic responses that, or DNA nanoparticles involving combinatorial use of in combination with conjugated functional nucleic acids various intrinsic functionalities. Although a host of issues have the potential of synergism. Since the first report including stability, safety and intracellular trafficking describing an aptamer-siRNA delivery approach in 2006 remain to be addressed, aptamers as simple functional many functional RNAs and DNAs conjugated to aptamer chimeras or as parts of multifunctional self-assembled sequences have been tested in vitro and in vivo [7-9]. -
Epitope Similarity Cannot Explain the Pre-Formed T Cell Immunity
www.nature.com/scientificreports OPEN Epitope similarity cannot explain the pre‑formed T cell immunity towards structural SARS‑CoV‑2 proteins Ulrik Stervbo 1,2,4*, Sven Rahmann 3,4*, Toralf Roch 1,2, Timm H. Westhof1 & Nina Babel1,2 The current pandemic is caused by the SARS‑CoV‑2 virus and large progress in understanding the pathology of the virus has been made since its emergence in late 2019. Several reports indicate short lasting immunity against endemic coronaviruses, which contrasts studies showing that biobanked venous blood contains T cells reactive to SARS‑CoV‑2 S‑protein even before the outbreak in Wuhan. This suggests a preformed T cell memory towards structural proteins in individuals not exposed to SARS‑CoV‑2. Given the similarity of SARS‑CoV‑2 to other members of the Coronaviridae family, the endemic coronaviruses appear likely candidates to generate this T cell memory. However, given the apparent poor immunological memory created by the endemic coronaviruses, immunity against other common pathogens might ofer an alternative explanation. Here, we utilize a combination of epitope prediction and similarity to common human pathogens to identify potential sources of the SARS‑CoV‑2 T cell memory. Although beta‑coronaviruses are the most likely candidates to explain the pre‑existing SARS‑CoV‑2 reactive T cells in uninfected individuals, the SARS‑CoV‑2 epitopes with the highest similarity to those from beta‑coronaviruses are confned to replication associated proteins—not the host interacting S‑protein. Thus, our study suggests that the observed SARS‑CoV‑2 pre‑formed immunity to structural proteins is not driven by near‑identical epitopes. -
Characterization of a Bifunctional Synthetic RNA Aptamer
www.nature.com/scientificreports OPEN Characterization of A Bifunctional Synthetic RNA Aptamer and A Truncated Form for Ability to Inhibit Growth of Non-Small Cell Lung Cancer Hanlu Wang1,2, Meng Qin2,3, Rihe Liu1,4, Xinxin Ding1,5, Irvin S. Y. Chen6 & Yongping Jiang1,2* An in vitro-transcribed RNA aptamer (trans-RA16) that targets non-small cell lung cancer (NSCLC) was previously identifed through in vivo SELEX. Trans-RA16 can specifcally target and inhibit human NCI-H460 cells in vitro and xenograft tumors in vivo. Here, in a follow-up study, we obtained a chemically-synthesized version of this RNA aptamer (syn-RA16) and a truncated form, and compared them to trans-RA16 for abilities to target and inhibit NCI-H460 cells. The syn-RA16, preferred for drug development, was by design to difer from trans-RA16 in the extents of RNA modifcations by biotin, which may afect RA16’s anti-tumor efects. We observed aptamer binding to NCI-H460 cells with KD values of 24.75 ± 2.28 nM and 12.14 ± 1.46 nM for syn-RA16 and trans-RA16, respectively. Similar to trans-RA16, syn-RA16 was capable of inhibiting NCI-H460 cell viability in a dose-dependent manner. IC50 values were 118.4 nM (n = 4) for syn-RA16 and 105.7 nM (n = 4) for trans-RA16. Further studies using syn-RA16 demonstrated its internalization into NCI-H460 cells and inhibition of NCI-H460 cell growth. Moreover, in vivo imaging demonstrated the gradual accumulation of both syn-RA16 and trans-RA16 at the grafted tumor site, and qRT-PCR showed high retention of syn-RA16 in tumor tissues.